Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8736233 | 0.72 | NCF1 (0.52) | — | |
| SCHEMBL17241821 | 0.71 | ALDH1A1 (0.35) | SLC18A3ALDH1A1 | |
| SCHEMBL14185936 | 0.70 | — | — | |
| SCHEMBL10190515 | 0.69 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL12725706 | 0.68 | ALDH1A1 (0.34) | ALDH1A1 | |
| SCHEMBL13935009 | 0.68 | SLC6A1 (0.37) | ALDH1A1 | |
| SCHEMBL17111070 | 0.68 | CHRM2 (0.30) | — | |
| SCHEMBL193932 | 0.68 | ITGB3 (0.43) | SLC18A3 | |
| SCHEMBL6726839 | 0.66 | GPR119 (0.37) | — | |
| SCHEMBL12575353 | 0.66 | PHGDH (0.38) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250144099-A1 | INK4 TUMOR SUPPRESSOR PROTEINS MEDIATE RESISTANCE TO CDK4/6 KINASE INHIBITORS | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2025-05-08 | — | — | US | disclosed |
| EP-4398911-A2 | INK4 TUMOR SUPPRESSOR PROTEINS MEDIATE RESISTANCE TO CDK4/6 KINASE INHIBITORS | Memorial Sloan Kettering Cancer Center (US) | 2024-07-17 | — | — | EP | disclosed |
| WO-2023039081-A2 | INK4 TUMOR SUPPRESSOR PROTEINS MEDIATE RESISTANCE TO CDK4/6 KINASE INHIBITORS | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2023-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250144099-A1 | INK4 TUMOR SUPPRESSOR PROTEINS MEDIATE RESISTANCE TO CDK4/6 KINASE INHIBITORS | CDK4, CDKN1A, CDK6 | SLC18A3 4758/4885ALDH1A1 1999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.